Moderna, Inc.

MRNA · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $19.3B · 4,700 employees
86
SEC Filings
$45.64
Close 2026-06-02
7
Transcripts
4,700
Employees

Business Summary

Moderna is a biotechnology company and pioneer in mRNA medicine, focused on developing vaccines and therapeutics across infectious disease, oncology, and rare disease. The company currently markets three commercial products: Spikevax and mNEXSPIKE (COVID-19 vaccines) and mRESVIA (RSV vaccine). In 2025, Moderna generated $1.9 billion in total revenue, primarily from COVID vaccine sales, while advancing a broader pipeline including individualized cancer therapies.

Latest Stock Quote

MRNA 2026-06-02 $45.64 O:$45.35 H:$46.17 L:$43.9 Vol:5.7M VWAP:$45.1682
origin leaf: 6bc6606df2638395bbdb2f7fdf2c89b76ea035bc8e83a3b0c377bc5633571746

Next Earnings

Q2 FY2026 — expected 2026-07-24

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionMRNAdiscussed Blockchain & Crypto
topic_mentionMRNAdiscussed Regulation
topic_mentionMRNAdiscussed Automotive
topic_mentionMRNAdiscussed Healthcare & Bio
topic_mentionMRNAdiscussed Capital Expenditure
topic_mentionMRNAdiscussed Supply Chain
topic_mentionMRNAdiscussed Regulation
topic_mentionMRNAdiscussed Automotive
topic_mentionMRNAdiscussed Healthcare & Bio
topic_mentionMRNAdiscussed Platform & Ecosystem
guidanceMRNAguided expect total revenue in 2025 to be in the range of $1.5 billion
guidanceMRNAguided expected to be approximately $1.1 billion
guidanceMRNAguided expect taxes to be negligible in 2025, and capital expenditures are projected to be approximately $400 million
guidanceMRNAguided expect to end 2025 with approximately $6 billion
guidanceMRNAguided forecast from $5.9 billion
guidanceMRNAguided guidance includes $0.9 billion
outlookMRNAstated We expect taxes to be negligible in 2025, and capital expenditures are projected to be approximately $400 million
outlookMRNAstated we expect to complete now by this summer
outlookMRNAstated We expect to have more clarity on the pace of case accrual and potential readout timing later this year
outlookMRNAstated We expect the potential for approval for M&A in 2028

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-202025-12-310001682852-26-000033EDGAR95K words
2025-02-212024-12-310001682852-25-000022EDGAR—
2024-02-232023-12-310001682852-24-000015EDGAR—
2023-02-242022-12-310001682852-23-000011EDGAR—
2022-02-252021-12-310001682852-22-000012EDGAR—
2021-02-262020-12-310001682852-21-000006EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001682852-25-000075EDGAR22K words
2025-08-012025-06-300001682852-25-000044EDGAR—
2025-05-012025-03-310001682852-25-000034EDGAR—
2024-11-072024-09-300001682852-24-000060EDGAR—
2024-08-012024-06-300001682852-24-000046EDGAR—
2024-05-022024-03-310001682852-24-000027EDGAR—
2023-11-032023-09-300001682852-23-000042EDGAR—
2023-08-032023-06-300001682852-23-000027EDGAR—
2023-05-042023-03-310001682852-23-000021EDGAR—
2022-11-032022-09-300001682852-22-000051EDGAR—
2022-08-032022-06-300001682852-22-000042EDGAR—
2022-05-042022-03-310001682852-22-000025EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-050001682852-26-000047EDGAR1K words
2026-02-130001682852-26-000015EDGAR—
2026-02-110001682852-26-000012EDGAR—
2026-01-120001682852-26-000007EDGAR—
2026-01-050001682852-26-000003EDGAR—
2025-11-240001628280-25-053816EDGAR—
2025-11-200001628280-25-053318EDGAR—
2025-11-130001628280-25-052055EDGAR—
2025-11-060001682852-25-000073EDGAR—
2025-08-010001682852-25-000041EDGAR—

86 total filings indexed. 58 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Earnings Transcripts

Call DateQuarterTitle
— MRNA Earnings Call Transcript
— MRNA Earnings Call Transcript
— MRNA Earnings Call Transcript
— MRNA Earnings Call Transcript
— MRNA Earnings Call Transcript
—Q1 FY3025MRNA Q1 FY3025 Earnings Call Transcript
—Q4 FY2025MRNA Q4 FY2025 Earnings Call Transcript

Access full transcripts via API (JSON) — includes speakers, key metrics, competitive mentions, and origin provenance chain.

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Tags

infectious-disease-vaccines oncology-therapeutics rare-disease-therapeutics respiratory-vaccines individualized-cancer-therapy mrna-medicine-platform individualized-neoantigen-therapy

Company Identity

CIK0001682852
TickerMRNA
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE
Websitehttps://www.modernatx.com
Listed2018-12-07

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 994bfb3d252ad19bcc1861ebf2de5525313e5e8e3d85346c67870361f0a090bd
parent: cd956d37333fc496f126b601b2e8a80a966e24c476e785c191f012f71697a19c
content hash: a486f3c30b09ab7663877990bc794f64c9865844a0c7187bcc08c4128796cf36
signed: 2026-06-03T12:01:54.258Z
sources: 26 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf